Asset Publisher

null José M Miró´s group


Cohort studies, early and advanced HIV infection, Tuberculosis and other opportunistic infections, clinical trials, solid organ transplantation.

Our team is currently working in the following research areas:

  1. HIV adult cohort studies. Dr. JM Miro is coordinating with Dr. Jordi Casabona the PISCIS cohort study which is including consecutive antiretroviral naïve and experienced adult patients from 15 Catalonian and Balearic Island hospitals since 1997. Research is focused on epidemiological and clinical studies. The PISCIS cohort is participating in the following international cohort studies: COHERE, ART-CC and EuroCOORD. In addition, our team is participating since 2004 in the RIS-Biobank. 
  2. Early (acute/recent) HIV infection. The research is focused on epidemiological studies of transmitted drug resistance (TDR) and in clinical trials with new antiretroviral drugs and/or immune modulators trying to change the natural history of HIV-infection. The Hospital Clinic PHI Cohort was created in 1997 and it has a biobank of biological and tissue samples since 2004. This team is coordinating the PHI-IMMUNOMEDIATED clinical trial and is participating in the following international trials: SPARTAC, MARAVIBOOST and ChAd-MVA.HIVconsv-BCN01 VACCINE. 
  3. Advanced HIV infection. The research of this lines is focused on immune reconstitution studies evaluating the efficacy and safety of different antiretroviral regimens in very advanced antiretroviral naïve patients (CD4<100 cells/mm3) and in evaluation their impact on bacterial translocation, inflammation and coagulation. This team is currently coordinating the ADVANZ-3 Clinical Trial. 
  4. Tuberculosis and other opportunistic infections. Dr. Miro is coordinating with Dr. Joan Caylà the Tuberculosis (TB) Trials Consortium (TBTC) Site 31 which is participating in clinical trials of treatment of latent TB infection and TB disease with the aim of shortening the duration of both treatments for full susceptible isolates and in trials forf MDR-TB treatment. The team is also participating in the TB-HIV EuroSida cohort. In addition the team is doing studies on Pneumocystis jiroveci pneumonia (PCP) and toxoplasmosis.    
  5. Solid organ transplantation. This team is coordinating the liver transplantation program in Spain and is doing studies in patients with kidney, combined kidney-pancreas and heart transplantation. These studies are focused on waiting list prognosis, mid/long-term survival, management of HCV recurrence and anti-HCV treatment, hepatocellular carcinoma (HCC), infections, rejection, efficacy and safety of antiretroviral therapy, PK interactions, neoplasms and retransplantation at national and international levels. In addition the prognostic factors of patients with end-stage liver and renal (dialysis) diseases is also analyzed

Related Assets


José M. Miró
Fernando Agüero
Juan Ambrosioni
Carmen Ligero
Christian Manzardo

Related Assets

Related Assets


  • Short-course antiretroviral therapy in primary HIV infection. 
    SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.  N Engl J Med. 2013 Jan 17;368(3):207-17 
  • The FIPSE OLT-HIV investigators. Liver Retransplantation in HIV-Infected Patients: A Prospective Cohort Study. 
    Gastaca M, Aguero F, Rimola A, Montejo M, Miralles P, Lozano R, Castells L, Abradelo M, Mata MD, San Juan Rodríguez F, Cordero E, Campo SD, Manzardo C, de Urbina JO, Pérez I, Rosa GD, Miro JM  Am J Transplant. 2012; 12:2465-2476. 
  • Spanish OLT in HIV-Infected Patients Working Group investigators. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. 
    Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Agüero F, Abradelo M, Miralles P, Torre-Cisneros J, Pedreira JD, Cordero E, de la Rosa G, Moyano B, Moreno A, Perez I, Rimola A  Am J Transplant. 2012; 12:1866-76. 
  • Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. 
    Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger SE, Martinez R, Sandler NG, Roque A, Liebner J, Battegay M, Bernasconi E, Descombes P, Erkizia I, Fellay J, Hirschel B, Miró JM, Palou E, Hoffmann M, Massanella M, Blanco J, Woods M, Günthard HF, de Bakker P, Douek DC, Silvestri G, Martinez-Picado J, Telenti A.  J Clin Invest. 2011; 121:2391-400. 
  • Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count inf. 200 cells/microL? 
    Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, Stephan C, De Wit S, Doerholt K, Ghosn J, Bucher HC, Lundgren JD, Chene G, Miro JM, Furrer H.  Clin Infect Dis. 2010; 51:611-9. 
  • Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. 
    Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM; Advanz Study Group.  AIDS Res Hum Retroviruses. 2010; 26: 747-57 
  • Progressive multifocal leukoencephalopathy in HIV-1 infection. 
    Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW.  Lancet Infect Dis. 2009; 9: 625-36. 
  • A whole-genome association study of major determinants for host control of HIV-1. 
    Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miró JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB.  Science. 2007; 317: 944-7. 
  • GESIDA 04/98 Study Group. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial 
    Miró JM, Lopez JC, Podzamczer D, Pena JM, Alberdi JC, Martinez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santin M, Ribera E  Clin Infect Dis. 2006; 43:79-89 
  • Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. 
    Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, Alos L, Ruiz A, Setoain J, Fumero E, Castro P, Lopez A, Cruceta A, Piera C, Florence E, Pereira A, Libois A, Gonzalez N, Guila M, Caballero M, Lomena F, Joseph J, Miro JM, Pumarola T, Plana M, Gatell JM, Gallart T.  J Infect Dis. 2005; 191:1680-5. 

Related Assets